George Simeon sold $720K of CRSP

George Simeon sold 14,514 shares of CRISPR Therapeutics AG (CRSP) at $49.63 ($0.72M total) on 2026-10-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · George Simeon
Published Oct 16, 2026, 9:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 9:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CRSP
Bearish
medium confidence
Mentioned
$CRSP
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRSPBearishLow
01

Why it matters

The disclosed sale may cause modest short-term price pressure but is unlikely to affect long-term outlook.

02

Market read

A director's insider sale of $720K is a modest, primary-source event that may slightly depress the stock.

03

What to watch

Potential tax planning or diversification needs of the director.

Relevance 4/10Novelty 4/10Timing: filing date 2026-10-16

Background

SEC Form 4 filing discloses an insider transaction by a director of CRISPR Therapeutics.

Company-level read

Ticker impact

$CRSPBearishMedium confidence
Context

Director George Simeon sold 14,514 shares for $720,373 via a 10b5-1 plan, reducing his stake to 15,486 shares.

Expected impact

likely slight downward pressure as investors price in the insider sell

Evidence & confidence

The sale is a routine insider transaction of modest size; markets typically react modestly to director sales.

Market effects

minimal impact on biotech sector

none

none

Counterpoint

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • CRISPR Therapeutics AG

    Biotech firm developing CRISPR gene-editing therapies.

  • George Simeon

    Director of CRISPR Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRSPMed

Seawolf Therapeutics San Diego $100M Sanofi DNA Deal

Seawolf Therapeutics, a San Diego biotech, raised $100M and partnered with Sanofi for a deal potentially worth $1.2B. The company's TRIDENT platform aims to enable repeat dosing of gene therapies. Seawolf's lead program targets metabolic diseases, with human trials expected by 2028. Investors include Eli Lilly, Novartis Venture Fund, and CRISPR Therapeutics.

$CRSPHighAI 8/10

Piper Sandler reiterates CRISPR Therapeutics stock rating at overweight

Piper Sandler maintained an Overweight rating and $110 price target for CRISPR Therapeutics (CRSP) after positive clinical data presentations. CTX310 showed significant reductions in lipid parameters, while zugo-cel demonstrated high response rates in various diseases. CRSP reported Q3 2026 sales of $99M for CASGEVY and holds $2.36B in cash. Analysts have mixed views on its valuation and price targets.

$CRSPMedAI 8/10

CRISPR Therapeutics reports trial results for gene therapy CTX310

CRISPR Therapeutics (CRSP) reported Phase 1b trial results for CTX310, a gene therapy for severe hypertriglyceridemia. The trial showed significant reductions in triglycerides, ANGPTL3 protein, and other cholesterol markers. No serious adverse events were reported. The FDA has granted RMAT designations to CTX310 for this indication and for elevated LDL cholesterol.